Fresenius Medical Care AG & Co. KGaA filed a Form 6-K containing Sarbanes-Oxley certifications for its unaudited financial statements as of and for the three-month period ended March 31, 2026, with no disclosure of financial results, operational metrics, or material corporate events.
Key takeaways
Certifications under Sections 302 and 906 of the Sarbanes-Oxley Act were filed by CEO Helen Giza and CFO Martin Fischer for the May 2026 6-K report.
The filing confirms the unaudited financial statements as of March 31, 2026 and for the three months ended March 31, 2026 and 2025 are fairly presented in all material respects.
No financial results (revenue, income, EPS), balance sheet data, cash flow metrics, or forward guidance were disclosed in the filing.
No executive changes, acquisitions, debt issuances, or other material corporate events were reported.